跳至主要内容
临床试验/DRKS00020290
DRKS00020290招募中不适用

RADprecise - Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity - RADprecise

Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center0 个研究点目标入组 1,050 人开始时间: 2020年1月3日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,050

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Adult breast or prostate cancer patients who received radiotherapy and have participated in the REQUITE study in Germany, Italy, Spain, UK and who are alive at re-contact
  • - Willingness and ability to comply with at least one scheduled visit
  • - The capacity to understand the patient information sheet and the ability to provide written informed consent

排除标准

  • - Re-irradiation of the region of initial radiotherapy (including contralateral breast)
  • - Any breast surgery after initial RT, mastectomy patients (including contralateral breast)
  • - Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires
  • - Known HIV infection, hepatitis B or hepatitis C not eligible for sample collection

研究者

相似试验